What Is the Best Strategy for Moderately Complex Femoropopliteal Lesions?

At present, PCI is the preferred treatment for femoropopliteal lesions and drug coated balloons (DCB) have shown good performance. However, they have not yet been shown superior to bare-metal stents (BMS). 

¿Cuál es la mejor estrategia en el territorio femoropoplíteo en lesiones de moderada complejidad?

This study compared randomized trials IN.PACT SFA I/II and IN.PACT JAPAN including 288 patients vs. the prospective Complete SE and DURABILITY II with 483 analyzed patients.

Final efficacy end point was primary patency defined as clinically driven target lesion revascularization (TLR) or freedom from restenosis at 12 months.

The populations were similar, mean age was 68, 65% were men, 90% presented hypertension, 40% diabetes, 6% required insulin, 34% were smokers and 50% had heart disease.

96% were in Rutherford 2-3 functional class. In 96% of cases, the superficial femoral was treated, 2.5% the popliteal, and 1.5% both. Lesion length was 80 mm, 33% were total occlusions and residual restenosis was higher in DCB patients (20% vs. 17.1% p<0.01). 

Read also: TAVR and New Onset LBBB.

Primary end point of efficacy resulted in favor of DCB (90.4% DCB vs. 80.9% BMS, P= 0.007). At 36 months, freedom for ischemia driven TLR also resulted in favor of DCB (85.6% DCB, 73.7% BMS, P= 0.001), as was MAE (25.3% DCB, 38.8% BMS, P < 0.001).

There were no differences at 3 years in all-cause mortality, major amputation or stent thrombosis. 

Conclusion

In this group of patients (based on the adjusted analysis of patients pooled from different studies) drug coated balloons showed better patency, lower need for revascularization and lower MAE rates, with no statistical difference in mortality, amputation or stent thrombosis, compared against conventional bare metal stents. This analysis supports the use of drug coated balloons in moderately complex lesions in femoropopliteal territory, where both strategies are viable. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease.

Reference: Mehdi H. Shishehbor, et al. J Am Coll Cardiol 2023;81:237–249.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...